Can amitriptyline be used in patients with Parkinson disease?

Use Amitriptyline with Caution in Parkinson's Disease

Amitriptyline can be used in Parkinson's disease for specific indications like depression or neuropathic pain, but it requires careful consideration of risks versus benefits, particularly given its anticholinergic effects and inclusion on the Beers Criteria for older adults.

Key Clinical Considerations

When Amitriptyline May Be Appropriate

For Depression in PD:

• Low-dose amitriptyline (25-75 mg/day) has demonstrated efficacy for treating depression in PD patients 1, 2, 3
• A 2006 American Academy of Neurology guideline states amitriptyline "may be considered" for depression in PD without dementia (Level C evidence) 3
• Studies show 72-83% responder rates with low doses (25-35 mg/day average) 1, 2
• However, 15% of patients discontinued due to side effects even at these low doses 1

For Neuropathic Pain:

• Amitriptyline should be considered for painful diabetic neuropathy (Level B recommendation) 4
• While these guidelines address diabetic neuropathy specifically, the principles may apply to other neuropathic pain conditions in PD

Critical Safety Concerns

Anticholinergic Effects (Major Concern): The FDA label explicitly warns about anticholinergic effects including 5:

• Urinary retention
• Angle-closure glaucoma risk
• Cognitive impairment/delirium
• Constipation
• Orthostatic hypotension

These effects are particularly problematic in PD patients who:

• Are typically older adults (mean age ~70 years)
• Already experience autonomic dysfunction
• May have cognitive impairment
• Are at high fall risk

Beers Criteria Warning:

• Amitriptyline is listed on the 2019 American Geriatrics Society Beers Criteria as potentially inappropriate in older adults 6
• The 2023 REM Sleep Behavior Disorder guideline specifically notes clonazepam is on the Beers list and cautions its use in older patients with neurodegenerative disease 7 - the same logic applies to amitriptyline

Cardiovascular Risks:

• Can cause arrhythmias, sinus tachycardia, and conduction delays 5
• Myocardial infarction and stroke reported with tricyclic antidepressants
• ECG screening recommended for patients >40 years 8
• Requires 6-8 weeks for adequate trial, limiting dosage to <100 mg/day when possible 8

Practical Prescribing Algorithm

Step 1: Assess if amitriptyline is truly necessary

• For depression: Consider SSRIs (sertraline, citalopram) or SNRIs (venlafaxine, duloxetine) as first-line alternatives 9, 10
• Sertraline showed better quality of life improvement than amitriptyline in one PD study 2
• For neuropathic pain: Consider pregabalin (Level A) or gabapentin (Level B) first 4, 11

Step 2: Screen for contraindications

• Cardiac disease (obtain ECG if >40 years)
• Urinary retention history
• Angle-closure glaucoma
• Cognitive impairment (use MMSE)
• Concurrent anticholinergic medications

Step 3: If proceeding with amitriptyline

• Start with 10-25 mg at bedtime 12, 1
• Titrate slowly by 10-25 mg increments
• Target dose: 25-75 mg/day (lower than typical antidepressant doses)
• Monitor for: orthostatic hypotension, urinary retention, cognitive changes, falls, cardiac symptoms
• Consider nortriptyline or desipramine as alternatives (secondary amine TCAs with fewer anticholinergic effects) 8, 9

Step 4: Ongoing monitoring

• Reassess benefit versus side effects at 3,6,9, and 12 months
• If inadequate response or intolerable side effects, switch to alternative agent
• Monitor for worsening motor symptoms, though studies suggest minimal motor impact 2, 3

Common Pitfalls to Avoid

1. Using standard antidepressant doses: PD patients respond to lower doses (25-75 mg vs. 150 mg typical) and tolerate them better 1

2. Ignoring drug interactions: Amitriptyline interacts with MAO-B inhibitors (selegiline, rasagiline) commonly used in PD 9, 5

3. Prescribing in patients with dementia: The 2006 AAN guideline specifically states amitriptyline may be considered for depression in PD "without dementia" 3

4. Overlooking the high PIM prevalence: Recent data shows amitriptyline was the most frequently prescribed potentially inappropriate medication in Korean PD patients 13

5. Not considering safer alternatives first: SSRIs/SNRIs are generally preferred in clinical practice despite similar efficacy 9, 10

Bottom Line

While amitriptyline has evidence supporting its use for depression and neuropathic pain in PD, it should not be a first-line choice given safer alternatives with comparable efficacy. If used, employ low doses (25-75 mg/day), screen carefully for contraindications, monitor closely for anticholinergic effects, and preferentially use in younger PD patients without cognitive impairment or significant autonomic dysfunction. The risk-benefit calculation favors SSRIs/SNRIs for depression and gabapentinoids for neuropathic pain in most PD patients.